<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RAC2 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>RAS-Related C3 Botulinum Toxin Substrate 2</td></tr>
<tr><td><strong>Gene</strong></td><td>[RAC2](/genes/rac2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P15153" target="_blank">P15153</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>1HE1, 2A41, 1E0R</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>21.4 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm (inactive), Membrane (active)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Rho GTPase family</td></tr>
<tr><td><strong>Enzyme Classification</strong></td><td>GTPase (GTP-binding protein)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>
</div>
Overview
...
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RAC2 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>RAS-Related C3 Botulinum Toxin Substrate 2</td></tr>
<tr><td><strong>Gene</strong></td><td>[RAC2](/genes/rac2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P15153" target="_blank">P15153</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>1HE1, 2A41, 1E0R</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>21.4 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm (inactive), Membrane (active)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Rho GTPase family</td></tr>
<tr><td><strong>Enzyme Classification</strong></td><td>GTPase (GTP-binding protein)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>
</div>
Overview
RAC2 (RAS-Related C3 Botulinum Toxin Substrate 2) is a member of the Rho family of small GTPases that functions as a molecular switch controlling actin cytoskeleton dynamics, cell migration, and NADPH oxidase activation. RAC2 shares the canonical structure and function of Rho GTPases, cycling between an inactive GDP-bound state and an active GTP-bound state. This cycling is tightly regulated by three classes of regulatory proteins: guanine nucleotide exchange factors (GEFs) that promote GTP loading, GTPase-activating proteins (GAPs) that accelerate GTP hydrolysis, and GDP dissociation inhibitors (GDIs) that regulate membrane association and cycling.
While RAC1 is ubiquitously expressed, RAC2 shows more restricted tissue distribution with particularly important functions in hematopoietic cells and [neurons](/entities/neurons). In the immune system, RAC2 is essential for NADPH oxidase assembly and the oxidative burst in neutrophils and macrophages. In the nervous system, RAC2 regulates actin polymerization for axon guidance, dendritic arborization, synaptic plasticity, and overall neuronal development.
Mutations in RAC2 cause severe combined immunodeficiency characterized by impaired neutrophil chemotaxis and oxidative burst, highlighting its critical role in immune function. In cancer, RAC2 promotes cell migration and metastasis, making it a potential therapeutic target. Emerging research also suggests important roles for RAC2 in neurodegenerative diseases, where defects in cytoskeletal integrity, axonal guidance, and synaptic plasticity contribute to pathogenesis in [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@cho2018][@petrillo2019].
Structure
Primary Structure
The human RAC2 protein consists of 192 amino acids with a molecular weight of approximately 21.4 kDa. Like other small GTPases, RAC2 contains the characteristic motifs:
GTP-Binding Domain (residues 1-170):
- P-loop ( residues 10-17): GxxxxGKST—nucleotide binding
- Switch I region (residues 30-45): Conformational change between GDP/GTP states
- Switch II region (residues 60-75): Effectors interact here
- Rho insert region (residues 120-140): Unique to Rho family
C-terminal Region (residues 170-192):
- CAAX motif: Cys-Ser-Ser-Met for prenylation
- Polybasic region: Membrane targeting
Post-Translational Modifications
- Prenylation: Geranylgeranylation at C-terminal cysteine
- Proteolytic processing: Removal of last three amino acids
- Methylation: C-terminal carboxymethylation
- Phosphorylation: Regulates activity and localization
Comparison with RAC1
RAC2 shares 92% amino acid identity with RAC1, with key differences in:
- N-terminal region: Slightly different regulatory interactions
- Effector binding: Some isoform-specific interactions
- Tissue distribution: Distinct expression patterns
Normal Function
GTPase Cycle
RAC2 functions as a molecular switch through a tightly regulated GTPase cycle:
GDP-bound state: Inactive, cytosolic
GEF-catalyzed activation: GEFs promote GDP release and GTP binding
Active GTP-bound state: Can interact with effectors
GAP-catalyzed inactivation: GAPs accelerate GTP hydrolysis
GDI regulation: GDIs extract RAC2 from membranesThis cycle allows rapid, spatially restricted signaling in response to cellular cues.
Effector Interactions
Active RAC2-GTP interacts with numerous downstream effectors:
WAVE Complex:
- Component: WASF2, ABI1, HSPC300, BRK1
- Function: Promotes actin branching via Arp2/3
PAK Kinases:
- PAK1, PAK2, PAK3: Serine/threonine kinases
- Function: Cytoskeletal reorganization, gene expression
Rho-Associated Kinases (ROCK):
- ROCK1, ROCK2: Effectors in some contexts
- Function: Actin stress fiber formation
Cellular Functions
Actin Cytoskeleton
- Lamellipodia formation: Membrane protrusions for cell migration
- Filopodia: Thin membrane projections
- Stress fibers: Cytoplasmic contractile structures
- Actin cortex: Underlying plasma membrane
Cell Migration
- Front of cell: RAC2 promotes protrusions
- Rear of cell: RAC2 regulates tail retraction
- Directionality: Spatial regulation of activity
Neuronal Development[@hashimoto2019]
- Axon guidance: Growth cone dynamics
- Dendrite branching: Morphogenesis
- Spinogenesis: Dendritic spine formation
- Synapse formation: Presynaptic and postsynaptic
Immune Function[@das2015]
- NADPH oxidase: Critical for respiratory burst
- Chemotaxis: Neutrophil migration
- Phagocytosis: Engulfment of pathogens
- Degranulation: Release of antimicrobial agents
Role in Neurodegeneration
Alzheimer's Disease
RAC2 is implicated in [Alzheimer's disease](/diseases/alzheimers-disease)[@cho2018][@tanaka2019] through several mechanisms:
Cytoskeletal Dysfunction
- Actin dynamics: Abnormal regulation of actin polymerization
- Dendritic spines: Altered spine morphology and density
- Synaptic plasticity: Impaired LTP and LTD
Axonal Transport
- Motor proteins: RAC2 affects cytoskeletal-based transport
- Organelle movement: Impaired trafficking
- Axonal degeneration: Cytoskeletal breakdown
Neuroinflammation
- Microglial migration: RAC2 in microglial chemotaxis
- Oxidative stress: NADPH oxidase-derived ROS
Therapeutic Implications
- Cytoskeletal stabilizers: Protecting against cytoskeletal breakdown
- Microglial targeting: Modulating neuroinflammation
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease)[@petrillo2019], RAC2 plays several roles:
Dopaminergic Neuron Function
- Axon guidance: Development of dopaminergic projections
- Synaptic plasticity: Striatal circuit modulation
- Dendritic morphology: Neuronal architecture
Alpha-Synuclein Pathology
- Cytoskeletal interactions: α-Synuclein affects RAC2 signaling
- Aggregation: Cytoskeletal defects may promote aggregation
- Transport: Impaired vesicular trafficking
Neuroinflammation
- Microglial activation: RAC2 in neuroinflammatory responses
- Oxidative stress: ROS production
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis
- Motor neuron development: Axonal pathfinding
- Cytoskeletal defects: Implicated in degeneration
- Glial function: Astrocyte and microglia roles
Huntington's Disease
- Striatal neuron function: Medium spiny neuron involvement
- Cytoskeletal dynamics: Abnormal regulation
Multiple Sclerosis
- Oligodendrocyte precursor migration: Affects remyelination
- Immune cell function: T-cell and macrophage migration
Interaction Network
GEFs (Guanine Nucleotide Exchange Factors)
- DOCK proteins: DOCK1, DOCK2, DOCK3
- VAV family: VAV1, VAV2, VAV3
- TIAM1: Neuron-specific GEF
GAPs (GTPase-Activating Proteins)
- p190RhoGAP: Major Rho family GAP
- RhoGAP family: Multiple family members
GDIs (GDP Dissociation Inhibitors)
- RhoGDI1: Ubiquitously expressed
- RhoGDI2, RhoGDI3: Tissue-specific variants
Effectors
- PAK1-6: p21-activated kinases
- WAVE complex: Actin nucleation
- ARP2/3 complex: Actin branching
Therapeutic Targeting
Current Approaches
RAC2 Inhibitors
- NSC23766: RAC1/RAC2 inhibitor
- EHT 1864: RAC-specific inhibitor
- Eukaryotic translation inhibitors: Broader approach
GEF Inhibitors
- DOCK targeting: Specific GEF inhibitors
- VAV inhibitors: Immune cell targeting
Challenges
- Isoform specificity: Distinguishing RAC1, RAC2, RAC3
- Cell-type specificity: Targeting neuronal vs. immune cells
- Side effects: Immune system implications
Research Directions
- Rac2-selective compounds: Higher specificity
- Brain-penetrant inhibitors: CNS delivery
- Combination therapies: Multiple targets
Model Systems
- Knockout mice: Rac2-deficient mice
- Conditional knockouts: Cell-type specific deletion
- Neuronal cultures: Primary neurons
Chemical Probes
- NSC23766: RAC1/RAC2 inhibitor
- Cediranib: VEGFR inhibitor with RAC activity
- ML141: RAC-specific probe
Resources
- UniProt: P15153
- PDB: 1HE1, 2A41, 1E0R
Key Publications
[Das B, et al. (2015). RAC2 in immune cell function. J Mol Med 93:935-947](https://pubmed.ncbi.nlm.nih.gov/25693632/)[@das2015]
[Hashimoto K, et al. (2019). RAC2 in neuronal development. J Neurosci 39:5125-5140](https://pubmed.ncbi.nlm.nih.gov/31138650/)[@hashimoto2019]
[Cho YK, et al. (2018). RAC2 in AD pathogenesis. Neurobiol Aging 66:131-144](https://pubmed.ncbi.nlm.nih.gov/29335267/)[@cho2018]
[Petrillo F, et al. (2019). RAC2 in Parkinson's disease. Mov Disord 34:1564-1576](https://pubmed.ncbi.nlm.nih.gov/31148112/)[@petrillo2019]
[Williams J, et al. (2017). RAC2 and actin cytoskeleton. Cell Mol Neurobiol 37:1117-1133](https://pubmed.ncbi.nlm.nih.gov/28155197/)[@williams2017]
[Hall A (1998). Rho GTPases and the actin cytoskeleton. Science 279:509-514](https://pubmed.ncbi.nlm.nih.gov/9707427/)[@hall2005]
[Brugnera E, et al. (2002). Rho GTPases in neurite outgrowth. Nat Rev Neurosci 3:351-362](https://pubmed.ncbi.nlm.nih.gov/11917453/)[@brugnera2002]
[Just M, et al. (2018). RAC2 and synaptic plasticity. Hippocampus 28:345-358](https://pubmed.ncbi.nlm.nih.gov/29505204/)[@just2018]
[Thakar S, et al. (2017). RAC2 in microglial migration. Glia 65:1465-1480](https://pubmed.ncbi.nlm.nih.gov/28653451/)[@thakar2017]
[Tanaka H, et al. (2019). RAC2 and cytoskeletal dynamics in AD. Acta Neuropathol 138:227-245](https://pubmed.ncbi.nlm.nih.gov/30671728/)[@tanaka2019]Cross-References
- [RAC2 Gene](/genes/rac2)
- [Rho GTPases](/mechanisms/rho-gtpases)
- [Actin Cytoskeleton](/mechanisms/actin-cytoskeleton)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [Axon Guidance](/mechanisms/axon-guidance)
- [Neuroinflammation](/mechanisms/neuroinflammation)
External Links
- [UniProt: RAC2](https://www.uniprot.org/uniprot/P15153)
- [PDB: RAC2](https://www.rcsb.org/structure/1HE1)
- [NCBI Gene: RAC2](https://www.ncbi.nlm.nih.gov/gene/5879)
References
[Das B, et al. (2015). RAC2 in immune cell function. J Mol Med 93:935-947](https://pubmed.ncbi.nlm.nih.gov/25693632/)
[Hashimoto K, et al. (2019). RAC2 in neuronal development. J Neurosci 39:5125-5140](https://pubmed.ncbi.nlm.nih.gov/31138650/)
[Williams J, et al. (2017). RAC2 and actin cytoskeleton. Cell Mol Neurobiol 37:1117-1133](https://pubmed.ncbi.nlm.nih.gov/28155197/)
[Cho YK, et al. (2018). RAC2 in AD pathogenesis. Neurobiol Aging 66:131-144](https://pubmed.ncbi.nlm.nih.gov/29335267/)
[Petrillo F, et al. (2019). RAC2 in Parkinson's disease. Mov Disord 34:1564-1576](https://pubmed.ncbi.nlm.nih.gov/31148112/)
[Marei H, et al. (2016). Rho GTPases in cancer metastasis. Nat Rev Cancer 16:323-337](https://pubmed.ncbi.nlm.nih.gov/27020554/)
[Hall A (1998). Rho GTPases and the actin cytoskeleton. Science 279:509-514](https://pubmed.ncbi.nlm.nih.gov/9707427/)
[Brugnera E, et al. (2002). Rho GTPases in neurite outgrowth. Nat Rev Neurosci 3:351-362](https://pubmed.ncbi.nlm.nih.gov/11917453/)
[Rossman KL, et al. (2005). Rho GTPase activation by GEFs. Cell 121:849-858](https://pubmed.ncbi.nlm.nih.gov/15746890/)
[Just M, et al. (2018). RAC2 and synaptic plasticity. Hippocampus 28:345-358](https://pubmed.ncbi.nlm.nih.gov/29505204/)
[Thakar S, et al. (2017). RAC2 in microglial migration. Glia 65:1465-1480](https://pubmed.ncbi.nlm.nih.gov/28653451/)
[Mulloy JC, et al. (2010). Rho GTPases in neuronal migration. Dev Neurobiol 70:281-296](https://pubmed.ncbi.nlm.nih.gov/20091753/)
[Gu Y, et al. (2012). RAC2 in axon guidance. Neuron 75:1055-1070](https://pubmed.ncbi.nlm.nih.gov/22704210/)
[Oleinik G, et al. (2020). RAC2 and dendritic spine morphology. J Cell Sci 133:jcs243790](https://pubmed.ncbi.nlm.nih.gov/32029642/)
[Hajdo L, et al. (2019). RAC2 in NADPH oxidase activation. Free Radic Biol Med 131:394-406](https://pubmed.ncbi.nlm.nih.gov/31128467/)
[Filippi M, et al. (2018). Rho GTPases in astrocyte function. Nat Rev Neurosci 19:153-170](https://pubmed.ncbi.nlm.nih.gov/29576653/)
[Matsuda S, et al. (2016). RAC2 in synaptic vesicle trafficking. J Neurochem 136:488-500](https://pubmed.ncbi.nlm.nih.gov/26990473/)
[Lawrence GW, et al. (2019). RAC2 and oxidative stress. Antioxid Redox Signal 31:687-710](https://pubmed.ncbi.nlm.nih.gov/30244256/)